Compare DGII & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | JANX |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | DGII | JANX |
|---|---|---|
| Price | $42.52 | $13.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $48.80 | ★ $60.27 |
| AVG Volume (30 Days) | 300.2K | ★ 2.3M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $430,221,000.00 | $10,000,000.00 |
| Revenue This Year | $10.51 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $39.67 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $22.39 | $13.26 |
| 52 Week High | $48.00 | $61.59 |
| Indicator | DGII | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 31.15 |
| Support Level | $42.48 | $13.26 |
| Resistance Level | $45.13 | $14.30 |
| Average True Range (ATR) | 1.21 | 0.44 |
| MACD | -0.39 | 0.44 |
| Stochastic Oscillator | 8.14 | 47.58 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.